Entity
  • Acticor Biotech

    Created in 2013
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    410 4,189
  • Activities

  • Technologies

  • Entity types

  • Location

    29 Rue du Faubourg Saint-Jacques, 75014 Paris, France

    Paris

    France

  • Employees

    Scale: 11-50

    Estimated: 34

  • SIREN

    798483285
  • Engaged corporates

    14
    11 6
  • Added in Motherbase

    6 years, 1 month ago
Description
  • Value proposition

    To treat the acute phase of ischemic stroke !

    Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.

    Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
    Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.

    However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.

    This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
    The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

    biotechnology, monoclonal antibody, drug development, thrombosis, stroke, TIA, Stroke, AVC, and healthcare

  • Original language

    To treat the acute phase of ischemic stroke !

    Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.

    Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
    Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.

    However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.

    This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
    The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Corporate interactions BETA
Corporate TypeTweets Articles
Karista
Karista
Startup accelerator & VC, Venture Capital and Private Equity Principals
Karista
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

21 Mar 2024


Le Figaro
Le Figaro
Media, Newspaper Publishing
Le Figaro
Media, Newspaper Publishing
Other

23 Jan 2024


Anaxago
Anaxago
Startup accelerator & VC, Venture Capital and Private Equity Principals
Anaxago
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

30 Jul 2023


SATT Ouest Valorisation
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
Other

16 Nov 2023


La French Tech
La French Tech
Media, Government Administration
La French Tech
Media, Government Administration
Other

2 Jul 2023


Agoranov
Agoranov
Startup accelerator & VC, Technology, Information and Internet
Agoranov
Startup accelerator & VC, Technology, Information and Internet
Not capitalistic
Not partnership
Event

1 Aug 2018


Paris Biotech Santé
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Not capitalistic
Not partnership
Event

24 Jan 2020


Institut du Cerveau – Paris Brain Institute
Institut du Cerveau – Paris Brain Institute
Startup accelerator & VC, Biotechnology Research
Institut du Cerveau – Paris Brain Institute
Startup accelerator & VC, Biotechnology Research
Not capitalistic
Not partnership
Event

10 Apr 2018


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Not capitalistic
Not partnership
Event

17 Dec 2018

19 Feb 2024



Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Not capitalistic
Not partnership
Event

11 Dec 2018


Similar entities
Loading...
Loading...
Social network dynamics